Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels

MERS-CoV seronegative and seropositive camels received a single intramuscular dose of ChAdOx1 MERS, a replication-deficient adenoviral vectored vaccine expressing MERS-CoV spike protein, with further groups receiving control vaccinations. Infectious camels with active naturally acquired MERS-CoV inf...

Full description

Bibliographic Details
Main Authors: Alharbi, N, Qasim, I, Almasoud, A, Aljami, H, Alenazi, M, Alhafufi, A, Aldibasi, O, Hashem, A, Kasem, S, Albrahim, R, Aldubaib, M, Almansour, A, Temperton, N, Kupke, A, Becker, S, Abu-Obaidah, A, Alkarar, A, Yoon, I, Azhar, E, Lambe, T, Bayoumi, F, Aldowerij, A, Ibrahim, O, Gilbert, S, Balkhy, H
Format: Journal article
Language:English
Published: Springer Nature 2019
Description
Summary:MERS-CoV seronegative and seropositive camels received a single intramuscular dose of ChAdOx1 MERS, a replication-deficient adenoviral vectored vaccine expressing MERS-CoV spike protein, with further groups receiving control vaccinations. Infectious camels with active naturally acquired MERS-CoV infection, were co-housed with the vaccinated camels at a ratio of 1:2 (infected:vaccinated); nasal discharge and virus titres were monitored for 14 days. Overall, the vaccination reduced virus shedding and nasal discharge (p = 0.0059 and p = 0.0274, respectively). Antibody responses in seropositive camels were enhancedby the vaccine; these camels had a higher average age than seronegative. Older seronegative camels responded more strongly to vaccination than younger animals; and neutralising antibodies were detected in nasal swabs. Further work is required to optimise vaccine regimens for younger seronegative camels.

Similar Items